Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy;Wirksamkeit und sicherheit von etofibrat bei patienten mit nicht proliferativer diabetischer retinopathie

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 7, 2009, Pages 561-567

  Emmerich, K H ^a   Poritis, N ^b   Stelmane, I ^c   Klindzane, M ^d   Erbler, H ^e   Goldsteine, J ^d   Gortelmeyer R ^f  

^a KLINIKUM DARMSTADT   (Germany)

^b Central Ophthalmologist   (Latvia)

^c Ophthalmologist   (Latvia)

^d Baltic Institute of Pharmaceutical Investigation and Consulting   (Latvia)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Diabetic retinopathy; Etofibrate; Exudative macular disease; Lipo Merz retard

Indexed keywords

CHOLESTEROL; ETOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; CLOFIBRIC ACID; DRUG DERIVATIVE;

ARTICLE; BLOOD VESSEL INJURY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LASER COAGULATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISUAL ACUITY; ADOLESCENT; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PLACEBO EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; CLOFIBRIC ACID; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350438097     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109516     Document Type: Article

References (24)

1. Aiello L M. Perspectives on diabetic retinopathy. Am J Ophthalmology 2003 136 122-135
2. Aiello L P., Davis M D., Girach A et al. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007 125 318-324
3. Summary benchmarks for preferred practice patterns (November 2006). American Academy of Ophthalmology http://www.aao.org/education/guidlines/ benchmarks/index.cfm
4. American Diabetes association. Diabetic retinopathy. Diabetes Care 2002 25 (Suppl 1) 90-93
5. Caldwell R B., Bartoli M, Behzadian M A. et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005 6 511-524
6. Chew E Y., Ambrosius W T., Howard L T. et al. Rationale design and methods of the action to control cardiovascular risk in diabetes eye study (ACCORD-EYE). Am J Cardiol 2007 99 (12 A) 103i-111i
7. Chowdhury T A., Hopkins D, Dodson P M. et al. The role of serum lipids in exudative diabetic maculapathy: is there a place for lipid-lowering therapy. Eye 2002 16 689-693
8. EDTRS Group. Early photocoagulation for diabetic retinopathy. EDTRS report number 9. Ophthalmology 1991 98 766-785
9. Fong D S., Aiello L M., Ferris F L. et al. Diabetic retinopathy. Diabetes Care 2004 27 2540-2553
10. Fong D S., Aiello L P., Ferris F I. et al. Diabetic Retinopathy. Diabetes Care 2004 27 2540-2553
11. Freyberger H, Schifferdecker E, Schatz H. Regression of hard exsudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent. Med Klin 1994 89 594-597
12. Hammes H P., Bertram B, Bornfeld N et al. Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Evidenzbasierte Leitlinien DDG-Aktualisierung (11 / 2004). http://www.deutsche- diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/Uebersicht- leitlinien-evidenzbasiert.php
13. Jonas J B. Intravitreal triamcinolone acetonide for diabetic retinopathy. Der Ophthalmol 2007 39 96-110
14. Keech A, Simes R J., Barter P et al. FIELD Study Investigators: Effects of long-term fenofibrat therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 366 1849-1861
15. Kim J, Ahn J H., Kim J H. et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007 84 886-893
16. Mandelcorn M S., Blankenship G, Machemer R. Pars Plana Vitrektomie fort he management of severe diabetic retinopathy. Am J Ophthalmol 1976 81 561-570
17. Mohamed Q, Gillies M C., Wong T Y. Management of diabetic retinopathy: a systematic review. JAMA 2007 298 (8) 902-916
18. Neubauer A S., Ulbig M W. Laser treatment in diabetic retinopathy. Ophthalmologica 2007 221 95-102
19. Patel A, ADVANCE study group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 370 829-840
20. Schwartz S G., Flynn jr H W. Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res 2007 52 487
21. Series J J., Caslakke M J., Kilday C et al. Influence of etofibrat on low density lipoprotein metabolism. Atherosclerosis 1988 69 233-239
22. Tserentsoodol N, Gordiyenko N V., Pascual I et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis 2006 12 1319-1333
23. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998 317 703-713
24. Viswanath K, McGavin D D. Diabetic Retinopathy: clinical findings and management. Community Eye Health 2003 16 21-24